|
US224A
(en)
|
|
1837-06-03 |
|
Improvement in cotton-presses |
|
US4447A
(en)
|
|
1846-04-04 |
|
Car- wheel |
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
IT1190891B
(it)
|
1982-06-24 |
1988-02-24 |
Anic Spa |
Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
GB8308483D0
(en)
|
1983-03-28 |
1983-05-05 |
Health Lab Service Board |
Secretion of gene products
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4625014A
(en)
|
1984-07-10 |
1986-11-25 |
Dana-Farber Cancer Institute, Inc. |
Cell-delivery agent
|
|
ATE78515T1
(de)
|
1984-10-05 |
1992-08-15 |
Genentech Inc |
Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
|
|
US4963495A
(en)
|
1984-10-05 |
1990-10-16 |
Genentech, Inc. |
Secretion of heterologous proteins
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US5047336A
(en)
*
|
1985-10-30 |
1991-09-10 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
|
|
US5427780A
(en)
|
1985-10-30 |
1995-06-27 |
Biogen, Inc. |
Composition comprising Mullerian inhibiting substance-like polypeptides
|
|
EP0437427A4
(en)
|
1985-10-30 |
1992-07-01 |
Biogen, Inc. |
Cleaved dimers of mullerian inhibiting substance-like polypeptides
|
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4753794A
(en)
|
1986-06-24 |
1988-06-28 |
The General Hospital Corporation |
Use of mullerian inhibiting substance as a contraceptive agent
|
|
US5010055A
(en)
|
1986-06-24 |
1991-04-23 |
The General Hospital Corporation |
Use of EGF to reverse the contraceptive activity of MIS
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4925678A
(en)
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
GB8723662D0
(en)
|
1987-10-08 |
1987-11-11 |
British Bio Technology |
Synthetic gene
|
|
US5061641A
(en)
|
1988-04-01 |
1991-10-29 |
Immunomedics, Inc. |
Method for radiolabeling proteins
|
|
US5057301A
(en)
|
1988-04-06 |
1991-10-15 |
Neorx Corporation |
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
|
|
WO1989010971A1
(en)
|
1988-05-09 |
1989-11-16 |
The United States Of America, As Represented By Th |
Vector for secretion of proteins directly into periplasm or culture medium
|
|
US5759802A
(en)
|
1988-10-26 |
1998-06-02 |
Tonen Corporation |
Production of human serum alubumin A
|
|
JPH02117384A
(ja)
*
|
1988-10-26 |
1990-05-01 |
Tonen Corp |
酵母宿主によるヒト血清アルブミンａの製造
|
|
US5661126A
(en)
|
1989-01-19 |
1997-08-26 |
The General Hospital Corporation |
Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5693622A
(en)
|
1989-03-21 |
1997-12-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5436146A
(en)
|
1989-09-07 |
1995-07-25 |
The Trustees Of Princeton University |
Helper-free stocks of recombinant adeno-associated virus vectors
|
|
US5676954A
(en)
|
1989-11-03 |
1997-10-14 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5167616A
(en)
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5981276A
(en)
|
1990-06-20 |
1999-11-09 |
Dana-Farber Cancer Institute |
Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
|
|
US5641671A
(en)
|
1990-07-06 |
1997-06-24 |
Unilever Patent Holdings B.V. |
Production of active Pseudomonas glumae lipase in homologous or heterologous hosts
|
|
WO1992013951A1
(en)
|
1991-02-04 |
1992-08-20 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Production of human serum albumin in methylotrophic yeast cells
|
|
US5225182A
(en)
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
CN1091138A
(zh)
|
1992-08-27 |
1994-08-24 |
迪金研究有限公司 |
疫苗
|
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
PT695169E
(pt)
|
1993-04-22 |
2003-04-30 |
Skyepharma Inc |
Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
|
|
US5914254A
(en)
|
1993-08-02 |
1999-06-22 |
Celtrix Pharmaceuticals, Inc. |
Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
|
|
PT729351E
(pt)
|
1993-11-16 |
2000-12-29 |
Skyepharma Inc |
Vesiculas com libertacao controlada de activos
|
|
US5665557A
(en)
|
1994-11-14 |
1997-09-09 |
Systemix, Inc. |
Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
|
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
|
US6495357B1
(en)
|
1995-07-14 |
2002-12-17 |
Novozyme A/S |
Lipolytic enzymes
|
|
WO1997014809A2
(en)
|
1995-10-16 |
1997-04-24 |
Dana-Farber Cancer Institute |
Novel expression vectors and methods of use
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
ES2257771T3
(es)
|
1996-10-28 |
2006-08-01 |
Amersham Health As |
Agentes de contraste.
|
|
US6180084B1
(en)
|
1998-08-25 |
2001-01-30 |
The Burnham Institute |
NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
|
|
US6361989B1
(en)
|
1997-10-13 |
2002-03-26 |
Novozymes A/S |
α-amylase and α-amylase variants
|
|
US6156552A
(en)
|
1998-02-18 |
2000-12-05 |
Novo Nordisk A/S |
Lipase variants
|
|
US6428978B1
(en)
*
|
1998-05-08 |
2002-08-06 |
Cohesion Technologies, Inc. |
Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
|
|
US6323007B1
(en)
|
1998-09-18 |
2001-11-27 |
Novozymes A/S |
2,6-β-D-fructan hydrolase enzyme and processes for using the enzyme
|
|
US6180367B1
(en)
|
1998-10-28 |
2001-01-30 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
JP4732591B2
(ja)
|
1999-03-29 |
2011-07-27 |
ノボザイムス アクティーゼルスカブ |
分枝酵素活性を有するポリペプチド及びそれをコードする核酸
|
|
EP1074265A1
(en)
|
1999-08-03 |
2001-02-07 |
Erasmus Universiteit Rotterdam |
Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
|
|
US6558939B1
(en)
|
1999-08-31 |
2003-05-06 |
Novozymes, A/S |
Proteases and variants thereof
|
|
WO2001019387A1
(en)
|
1999-09-14 |
2001-03-22 |
The General Hospital Corporation |
Use of mullerian inhibiting substance for treating excess androgen states
|
|
US6673352B1
(en)
|
1999-09-14 |
2004-01-06 |
The General Hospital Corporation |
Use of Mullerian inhibiting substance for treating excess androgen states
|
|
DE19944870A1
(de)
|
1999-09-18 |
2001-03-29 |
Aventis Pharma Gmbh |
Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
|
|
US6617143B1
(en)
|
1999-10-20 |
2003-09-09 |
Novozymes A/S |
Polypeptides having glucanotransferase activity and nucleic acids encoding same
|
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
US6509181B1
(en)
|
2000-04-14 |
2003-01-21 |
Novozymes, A/S |
Polypeptides having haloperoxide activity
|
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
|
US7202059B2
(en)
|
2001-02-20 |
2007-04-10 |
Sanofi-Aventis Deutschland Gmbh |
Fusion proteins capable of being secreted into a fermentation medium
|
|
CA2457918C
(en)
|
2001-08-20 |
2013-11-26 |
David B. Seifer |
Mullerian inhibiting substance levels and ovarian response
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
WO2005030963A1
(en)
|
2003-09-26 |
2005-04-07 |
Applied Research Systems Ars Holding N.V. |
Leader sequences for use in production of proteins
|
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
|
CA2516364A1
(en)
|
2005-03-24 |
2006-09-24 |
University Of Otago |
Method of modulation
|
|
EP1951277A2
(en)
|
2005-10-14 |
2008-08-06 |
Biorexis Pharmaceutical Corporation |
Natriuretic peptide modified transferrin fusion proteins
|
|
JP2009515832A
(ja)
|
2005-10-26 |
2009-04-16 |
オタゴ イノベーション リミテッド |
神経変性疾患の治療のためのミュラー管抑制物質（ｍｉｓ）受容体のモジュレーション方法
|
|
JP5714230B2
(ja)
|
2007-01-31 |
2015-05-07 |
フェネックス インコーポレイテッド |
発現上昇のための細菌リーダー配列
|
|
US20100233689A1
(en)
|
2007-03-22 |
2010-09-16 |
The General Hospital Corporation |
Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
|
|
WO2009012357A2
(en)
|
2007-07-17 |
2009-01-22 |
The General Hospital Corporation |
Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
|
|
US10457719B2
(en)
|
2007-09-18 |
2019-10-29 |
The Jackson Laboratory |
Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
|
|
WO2010017290A1
(en)
|
2008-08-05 |
2010-02-11 |
The Trustees Of Columbia University In The City Of New York |
Müllerian inhibiting substance (mis) analogues
|
|
EP2412800A1
(en)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Liver organoid, uses thereof and culture method for obtaining them
|
|
FR2993926A1
(fr)
|
2012-07-24 |
2014-01-31 |
Vianney Rabhi |
Turbomoteur basse-pression a combustion interne et/ou externe
|
|
ES2853935T3
(es)
|
2013-03-12 |
2021-09-20 |
Massachusetts Gen Hospital |
Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
|
|
US10258668B2
(en)
|
2013-09-20 |
2019-04-16 |
The General Hospital Corporation |
Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
|
|
US11135269B2
(en)
|
2013-12-11 |
2021-10-05 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
|
US20240218038A1
(en)
|
2021-03-22 |
2024-07-04 |
The General Hospital Corporation |
Compositions and methods for preventing or delaying puberty in prepubescent non-human animals and humans
|